Advanced Heart Failure and Transplant Cardiology · Rochester, MN
NPI
1740480391
Since 2007
Specialty
Advanced Heart Failure and Transplant Cardiology
Code 207RA0001X
Group practices
4
Medicare group memberships
Hospitals
3
Hospital affiliations
200 1st St SW
Rochester, MN, 55905
Phone (507) 284-2511
Groups this clinician bills Medicare through
Medicare paid, 2024
$50K
664 services
Medicare patients, 2024
311
Average age 74
Drug cost, 2024
$6.2M
1,211 prescriptions
Company payments, 2024
$4,600
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Omar F Abou Ezzeddine was code 99233 (hospital e&m - subsequent), 234 times for 84 patients. In total Omar F Abou Ezzeddine billed 664 services in 21 codes, and Medicare paid $50K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-08-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99233 Hospital E&M - Subsequent | Facility | 234 | 84 | $94.60 | $22K |
| 93018 Electrocardiogram | Facility | 108 | 108 | $10.92 | $1,179 |
| 93016 Electrocardiogram | Facility | 108 | 108 | $16.60 | $1,793 |
| 99215 Office E&M - Established | Office | 65 | 55 | $144.93 | $9,420 |
| 99205 Office E&M - New | Office | 38 | 38 | $179.05 | $6,804 |
| 99222 Hospital E&M - Initial | Facility | 33 | 33 | $94.25 | $3,110 |
| 99204 Office E&M - New | Office | 20 | 20 | $135.64 | $2,713 |
By year: 2022 $54K for 784 services; 2023 $51K for 717 services; 2024 $50K for 664 services.
Medicare prescription drug claims, 2024
In 2024, the drug Omar F Abou Ezzeddine prescribed most often to Medicare patients was Vyndamax (Tafamidis), with 171 prescriptions and refills. In total Omar F Abou Ezzeddine wrote 1,211 Medicare prescriptions that cost $6.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Vyndamax Tafamidis | 171 | 187 | 18 | $4.1M |
| Jardiance Empagliflozin | 120 | 267 | 32 | $149K |
| Metoprolol Succinate Generic | 109 | 306 | 35 | $2,705 |
| Entresto Sacubitril/Valsartan | 104 | 240 | 29 | $153K |
| Vyndaqel Tafamidis Meglumine | 76 | 76 | Under 11 | $1.7M |
| Spironolactone Generic | 69 | 167 | 25 | $510 |
| Atorvastatin Calcium Generic | 67 | 115 | 15 | $690 |
| Torsemide Generic | 46 | 131 | 18 | $2,788 |
| Eliquis Apixaban | 46 | 112 | 16 | $65K |
| Furosemide Generic | 44 | 109 | 11 | $222 |
| Farxiga Dapagliflozin Propanediol | 44 | 86 | 12 | $44K |
| Carvedilol Generic | 36 | 92 | 15 | $346 |
| Losartan Potassium Generic | 30 | 90 | 11 | $391 |
| Amlodipine Besylate Generic | 25 | 25 | Under 11 | $261 |
| Donepezil Hcl Generic | 25 | 25 | Under 11 | $307 |
Brand drugs: 599 claims; generic drugs: 612 claims.
Money and other things of value reported by the companies
In 2024, drug and medical device companies paid Omar F Abou Ezzeddine $4,600 ($4,600 in general payments such as food, travel and fees) from 1 company. The largest payer was Pfizer Inc. with $4,600.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 1 | $4,600 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.